medac to strengthen its presence in the Middle East

14 October 2025

German active pharmaceutical ingredients company Medac, specializing in therapeutic solutions for oncology, rheumatology, urology and hematology, today announced the acquisition of Biotech Pharma, based in Dubai.

Following this acquisition, medac will establish its own entity, medac pharma LLC, that will be managed and operated by the experienced Biotech Pharma team. No financial terms were disclosed.

“The establishment of medac pharma LLC marks a major milestone in our journey towards deeper regional integration,” said Frank Lucaßen, chef executive at medac.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK